C ancer genomes are subject to continuous mutagenic processes in combination with insufficient DNA damage repair 1 . Somatic genomic variants that are acquired prior to and throughout tumorigenesis may provide cancer cells with a competitive advantage over their neighboring cells in the context of a nutrition-and oxygen-poor microenvironment, resulting in increased survival and/or proliferation rates 2 . The Darwinian evolutionary process results in intratumoral heterogeneity in which tumor subclones derived from single cancer cells are characterized by unique somatic alterations 3 . Chemotherapy and ionizing radiation may enhance tumor evolution by eliminating cells lacking the ability to cope with increased levels of genotoxic stress, while targeted therapy may favor subclones in which the targeted vulnerability is absent 4,5 . Increased clonal heterogeneity has been associated with tumor progression and mortality 6 . Computational methods that analyze the allelic fraction of somatic variants identified from high-throughput sequencing datasets are able to infer clonal population structures and provide insights into the level of intratumoral clonal variance 7 .
C ancer genomes are subject to continuous mutagenic processes in combination with insufficient DNA damage repair 1 . Somatic genomic variants that are acquired prior to and throughout tumorigenesis may provide cancer cells with a competitive advantage over their neighboring cells in the context of a nutrition-and oxygen-poor microenvironment, resulting in increased survival and/or proliferation rates 2 . The Darwinian evolutionary process results in intratumoral heterogeneity in which tumor subclones derived from single cancer cells are characterized by unique somatic alterations 3 . Chemotherapy and ionizing radiation may enhance tumor evolution by eliminating cells lacking the ability to cope with increased levels of genotoxic stress, while targeted therapy may favor subclones in which the targeted vulnerability is absent 4, 5 . Increased clonal heterogeneity has been associated with tumor progression and mortality 6 . Computational methods that analyze the allelic fraction of somatic variants identified from high-throughput sequencing datasets are able to infer clonal population structures and provide insights into the level of intratumoral clonal variance 7 .
GBM, a World Health Organization (WHO) grade IV astrocytoma, is the most prevalent and aggressive primary central nervous system tumor. GBM is characterized by poor response to standard post-resection radiation and cytotoxic therapy, resulting in dismal prognosis with a 2-year survival rate around 15% 8 . The genomic and transcriptomic landscape of GBM has been extensively described [9] [10] [11] . Intratumoral heterogeneity in GBM has been well characterized, in particular with respect to somatic alterations affecting receptor tyrosine kinases [12] [13] [14] . To evaluate how genomically heterogeneous tumor cell populations are affected by selective pressures arising from the transitions from tumor to culture to xenograft, we performed a comprehensive genomic and transcriptomic analysis of 13 GBMs, the glioma-neurosphere-forming cultures (GSCs) derived from them and orthotopic xenograft models (PDXs) established from early-passage neurospheres. Our results highlight the evolutionary process of GBM cells, placing emphasis on the diverging dynamics of chromosomal DNA alterations and extrachromosomally amplified DNA elements in tumor evolution.
Articles
NATuRe GeNeTIcs model systems capture the somatic alterations that are thought to drive gliomagenesis, and whether there is selection for specific driver genes, we performed whole-genome sequencing at a median depth of 6.5× to determine genome-wide DNA copy number as well as exome sequencing on all samples. DNA copy number was generally highly preserved between the tumor and derived model systems ( Supplementary Fig. 1 ). Whole chromosome 7 gain and chromosome 10 loss were retained in model systems when detected in the tumor, consistent with their proposed role as canonical GBM lesions that occur among the earliest events in gliomagenesis 15 . The global DNA copy number resemblance between xenografts and the GBMs from which they were derived confirms that PDXs recapitulate the majority of molecular properties found in the original tumor.
We compared the mutation and DNA copy number status of genes previously found to be significantly mutated, gained or lost in GBM 9, 11 . We found that 100% of homozygous deletions and somatic single-nucleotide variants (sSNVs) affecting GBM driver genes in tumor samples were propagated to the neurospheres and xenografts, including noncoding variants in the TERT promoter ( Fig. 1b) . Genomic amplifications showed greater heterogeneity. In two cases, MYC amplification was not detected in the parental tumor but was present in the derivative neurospheres and was maintained in Articles NATuRe GeNeTIcs xenografts, consistent with its role in glioma stem cell maintenance 16, 17 .
Other genes showing variable representation across tumor and model systems included MET in HF-3035 and HF-3077 and EGFR and PIK3CA in HF-2354. The HF-2354-derived model systems were considerably less similar to the primary tumor than in other cases, which coincided with HF-2354 being the only case subjected to neoadjuvant carmustine treatment. Whole-chromosome gains of chromosomes 1, 14 and 21 and one-copy loss of chromosomes 3, 8, 13, 15 and 18 were acquired in the neurosphere culture and propagated to the xenograft models ( Supplementary Fig. 1) . At the gene level, this resulted in newly detected mutations in PTEN and TP53, focal amplification of MYC (also in HF-3016), and absence of CDK4 and EGFR amplification in the neurosphere culture and xenografts relative to the tumor sample ( Fig. 1b ).
Extrachromosomal elements are frequently found in glioblastoma. Cytogeneticists have long recognized that DNA in cancer can be amplified as part of chromosomal homogenously staining regions (HSRs) and as extrachromosomal minute bodies 18 . An early example of the importance of ecDNAs in cancer was the discovery of double minutes carrying the oncogene NMYC in neuroblastoma 19 .
A recent survey of a compendium of cancer cells and cell lines highlighted the frequent presence of ecDNA in GBM, among other cancer types 20 , confirming previous studies [21] [22] [23] . We searched our dataset for complex patterns of DNA copy number amplification and rearrangement that are suggestive of ecDNA elements ( Supplementary  Fig. 2 ). In addition, we ran the AmpliconArchitect algorithm, which detects ecDNAs in an unsupervised manner on the basis of sequencing reads connecting amplified DNA segments 20 . Taking the union of AmpliconArchitect predictions and DNA copy number patterns, we predicted 93 ecDNAs originating from 79 unique genomic loci, which were distributed over 49 of the 13 patient tumors and their derived model systems (Supplementary Table 2 ). The predicted ecDNA elements contained oncogenes including MYC, MYCN, EGFR, PDGFRA, MET, the MECOM-PIK3CA-SOX2 gene cluster and the CDK4-MDM2 gene cluster. In total, 22 of the 25 ecDNAs carrying an oncogene were detected in multiple samples from the same patient ( Fig. 2a ). We performed interphase FISH on tumor samples and PDXs and metaphase FISH on neurospheres to validate 34 predicted ecDNA amplifications, including of EGFR (HF-2927, HF-3178, HF-3016 and HF-3177), MYC (HF-2354, HF-3016 and HF-3177), CDK4 (HF-3055, HF-3016 and HF-3177), MET (HF-3035 and HF-3077), MDM2 (HF-3055) and PDGFRA (HF-3253). In all interphase FISH experiments, we observed a highly variable number of fluorescent signals per nucleus, ranging from 2 to 100 ( Fig. 2b and Supplementary Table 3 ). This heterogeneity is strongly suggestive of differences in the number of DNA copies of the targeted gene per cell and thereby of an ecDNA amplification. Metaphase FISH on neurosphere cells validated extrachromosomal status in all cases ( Fig. 2b ). Our analysis shows that oncogene amplification frequently resides on ecDNA elements.
Extrachromosomal MET DNA elements mark a distinct tumor subclone. Among the identified oncogene-carrying ecDNA elements, two cases of extrachromosomal MET amplification stood out owing to their variable presence across the parental tumor (high frequency), neurospheres (low frequency) and xenograft triplicates (high frequency) ( Fig. 3a) . In both cases, the MET amplification was associated with a transcript fusion with neighboring gene CAPZA2 ( Fig. 3b and Supplementary Fig. 3a ). Additional details on the CAPZA2-MET fusions are provided in the Supplementary Note. The pattern of undetectable and reappearing MET rearrangements may result from clonal selection of GBM cells with a competitive advantage for proliferation in vivo. This hypothesis is strengthened by the observation that the breakpoints of the lesions were identical across samples from the same parental origin ( Supplementary Fig. 3b ).
MET is a growth-factor-responsive cell surface receptor tyrosine kinase and may provide context-dependent proliferative signals 24 . We reasoned that evolutionary patterns resulting in such dominant clonal selection would likely be replicated by sSNVs tracing the cells carrying the MET amplicon. To evaluate clonal selection patterns, we determined the variant allele fractions of all sSNVs identified across the HF-3035 and HF-3077 samples. To increase our sensitivity in detecting mutations present in small numbers of cells, we corroborated the exome sequencing data using highcoverage (> 1,400× ) targeted sequencing. All mutations detected in the HF-3035 GBM were recovered in the neurosphere culture and xenografts. The mutational profile of HF-3035 suggested that a subclone developed in the xenografts that was not present in the parental GBM and neurospheres and identified a subclone that was present at similar frequencies in all samples ( Fig. 3c ). Only a single and very low-frequency LAMB1 mutation (variant allele fraction in tumor = 0.003) present in the HF-3077 primary tumor, but not detected in its derived neurosphere, resurfaced in one of the three xenografts with a variant allele fraction of 0.04. A low-frequency subclone (C2) developed in the neurosphere culture that was transmitted to the xenografts ( Fig. 3c ). Subclonal heterogeneity as recovered by the mutation profiles thus suggests a very different clonal selection trend than the disappearing and resurfacing MET amplifications and associated transcript fusions. EcDNAs are thought to be randomly inherited by two daughter cells 25 , possibly through a binomial model 26 , but much is unknown with respect to the propagation of ecDNA through cancer cell populations. The disjointed propagation of chromosomal sSNVs and MET-carrying ecDNAs indicates that they are marking different tumor subclones and suggests alternative modes of tumor evolution. While sSNVs are copied to daughter cells during mitosis such that both cells inherit the full spectrum of chromosomal alterations present in the parental cell, ecDNA elements likely randomly segregate and end up in daughter cells in uneven numbers. MET-expressing cells exhibited MET activation and were selected early during tumor formation in the orthotopic xenografts ( Supplementary Fig. 3c ), suggesting that MET activity was driving selection for MET-amplified cells in vivo. Treatment of HF-3077 PDXs with the ATP-competitive MET inhibitor capmatinib (INCB28060) 27 at a daily oral dose of 30 mg/kg resulted in a significant survival benefit, despite the relatively low concentration of drug in the brain tumor as assessed by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) ( Fig. 3d ). In contrast, capmatinib treatment of HF-3035 PDXs did not increase survival or decrease MET expression, but resulted in a decrease in the levels of phosphorylated MET in treated tumors. This may reflect MET functions that are independent of its kinase activity in these tumors, as previously proposed 28, 29 . These results demonstrate that targeting MET in GBM harboring MET ecDNA amplification has therapeutic potential, but further work is needed to establish the factors determining the sensitivity of MET-amplified tumors to single-agent ATP-competitive inhibitor treatment. Comparable to the orthotopic xenografts, subcutaneous PDX tumors formed from the implantation of HF-3035 neurosphere cells were dominated by MET-amplified cells accompanied by robust MET expression ( Supplementary Fig. 3c ). The increase in the frequency of MET amplification in HF-3035 cells in vivo is therefore not dependent on factors uniquely present in the brain microenvironment.
Different genetic origins for ecDNA have been postulated, with evidence for postreplicative excision of chromosomal fragments and non-homologous end joining 30 . Interphase FISH analysis in the parental HF-3077 tumor identified a small percentage of nuclei with three copies of chromosome 7 but only two copies of MET. The frequency of cells with one deleted copy of MET on chromosome 7 increased significantly in HF-3077 neurospheres and decreased in the xenografts (Supplementary Table 3 XENO_3  TS  NS  TS  NS  TS  NS  TS  NS  TS  NS  TS  NS  TS  NS  TS  NS  TS  NS  TS  NS  TS  NS  TS 
NATuRe GeNeTIcs deletion on one copy of chromosome 7 is suggestive of the postreplication segregation-based model of double-minute formation 30 . To precisely define the genomic contents and structure of the predicted ecDNAs, we generated long-read (Pacific Biosciences, PacBio) DNA sequencing from a single xenograft each of HF-3035 and HF-3077 and performed de novo assembly. In HF-3035, seven assembled contigs (range: 6,466-135,621 bp) were identified to have sequence fragments (at least 1,000 bp long) aligned on the MET-CAPZA2
region of hg19 chromosome 7. Interestingly, analysis of the aligned sequence fragments from the seven contigs highlighted a more complex structural rearrangement than expected from the analysis of short-read sequencing data. For example, the 135-kb tig01170337 contig consisted of eight sequence fragments that were nonlinearly aligned on alternating strands of the MET-CAPZA2 and CNTNAP2 regions. Other contigs such as tig01170699, tig01170325 and tig00000023 also showed nonlinear alignment, suggesting that these 
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contigs resulted from chromosomal structural variations. We performed pairwise sequence comparison of the contigs to search for sequence fragments (at least 5,000 bp long) shared among them, and we found four contigs that each shared sequence fragments with one of the contigs. Interestingly, three of them could be connected in a circular form using the shared sequence fragments ( Fig. 3e and Supplementary Fig. 4a ), identifying a circular structure that may represent the full ecDNA. In HF-3077, only two contigs were detected to be aligned on the MET-CAPZA2 region of hg19 chromosome 7 ( Fig. 3e and Supplementary Fig. 4a ). The presence of only two aligned contigs in HF-3077 might be related to the lower sequence coverage of the ecDNA structure as compared to HF-3035 (34× versus 405× , respectively) ( Supplementary Fig. 4b ). The longest contig, tig01141776 (183,455 bp), consisted of two segment fragments that were nonlinearly aligned over exon 1 of CAPZA2 and all except exons 3-5 of MET, suggesting that it resulted from structural variations. The second short contig, tig01141835 (22,628 bp), was aligned as a whole over exons 3-5 of MET. Interestingly, connecting the two contigs created a circular DNA segment. Through analysis of PacBio sequencing, we were able to detect and reconstruct the predicted extrachromosomal element structures.
Multiple ecDNA elements are longitudinally preserved in a patient GBM and its derivative model systems. Analysis of a pair of primary and recurrent GBMs included in our cohort, respectively HF-3016 and HF-3177, showed that chromosomal and extrachromosomal elements jointly orchestrate complex evolutionary dynamics (Fig. 4a) . The primary and recurrent tumors were globally very similar ( Fig. 1b and Supplementary Fig. 1 ). While the HF-3016 primary tumor showed diploid MYC DNA copy numbers, a focal MYC amplification was detected in the neurosphere culture and PDXs derived from this tumor and the same MYC amplification was identified in all samples from the recurrent tumor ( Fig. 4b ). Interestingly, FISH analysis showed that MYC amplification was present at low frequency (2%) in the initial HF-3016 tumor and was enriched to 100% of nuclei in the neurospheres culture and in the recurrent tumor ( Fig. 4c and Supplementary Table 3 ). Metaphase FISH analysis confirmed extrachromosomal MYC amplification in both HF-3016 and HF-3177 neurospheres (Fig. 4c ). The sSNV-based clonal tracking plots for the paired patient samples identified two subclones in the HF-3177 recurrence ( Fig. 4d ) that were not detected in the HF-3016 neurosphere or PDX models, suggesting that these were independent of the MYC ecDNA element. Of note, an amplification with a cell frequency of 0.5% was also detected in the parental tumor sample of HF-2354, which increased to high levels in the derived neurospheres. DNA copy number analysis detected parallel EGFR and CDK4 amplifications in the HF-3016 primary GBM that were retained in the HF-3177 GBM recurrence as well as all model systems. Sequencing reads connecting the two amplifications and suggesting a complex structural variant were detected in the HF-3016 neurospheres, the HF-3016 PDXs and all HF-3177 samples, but not the HF-3016 primary GBM (Fig. 4e ). Metaphase FISH on HF-3016 neurospheres and HF-3177 neurospheres confirmed that the CDK4 and EGFR amplifications were part of the same ecDNA element (Fig. 4f) . The genomic and extrachromosomal characteristics of these two tumor samples and their derived neurosphere cultures and xenografts provide an example of how multiple ecDNA elements are able to be preserved during tumor progression while new tumor subclones marked by sets of chromosomal sSNVs are acquired in parallel.
Longitudinal maintenance of extrachromosomal DNA in patient tumors. Large, megabase-sized extrachromosomal elements, typically described as double minutes, are frequently found in GBM and can be identified using whole-genome sequencing and DNA copy number data [21] [22] [23] . To determine whether ecDNA can survive therapeutic barriers, we evaluated the DNA copy number profiles of 58 matching pairs of primary and recurrent glioma for the presence of ecDNA. Evidence supporting the presence of ecDNA was found in 33 primary and 33 recurrent tumors spanning 38 patients; of these, ecDNA elements targeting cancer driver genes 31 were predicted in 25 primary tumors ( Fig. 5a and Supplementary Table 2 ). The most frequently targeted gene was EGFR, which was identified in 14 primary tumors, in agreement with previous reports 22 . CDK4 and PDGFRA were detected in six and seven primary tumors, respectively. Crossreferencing the list of ecDNA predictions with a manually curated list of oncogenes suggests that 60% of ecDNAs target an oncogene. Consistent with oncogene amplification frequencies, IDH-wild-type tumors contained relatively more ecDNAs than IDHmutant tumors (medians of 2 and 1, respectively), but the fraction of samples with at least a single ecDNA was comparable (0.5 versus 0.6 for IDH-wild-type and IDH-mutant tumors, respectively). We corroborated our computational predictions through interphase FISH analyses of 18 predicted ecDNAs and 30 non-altered loci across seven primary-recurrent tumor pairs. Sixteen of 17 genomic amplifications showed the highly variable number of DNA signals that is strongly suggestive of an extrachromosomal nature of the DNA locus ( Fig. 5b and Supplementary Fig. 5 ), whereas the 26 control DNA regions predicted to be non-amplified were confirmed as such ( Supplementary Table 4 ). EGFR-harboring ecDNA was preserved in the recurrent tumor in 11 of 13 pairs, half of which carried an EGFRvIII mutation, including the HF-2934 recurrent tumor analyzed after treatment with the EGFR inhibitor dacomitinib ( Fig. 5b and Supplementary Table 4 ). One tumor lost an EGFR ecDNA and the EGFRvIII mutation upon recurrence (HF-2829), after treatment with the standard of care (radiation and temozolomide). In one case, MET ecDNA was present in the primary tumor and maintained in the recurrence, while MYC ecDNA emerged upon recurrence, similar to what we report above for the HF-3016-HF-3177 pair. To corroborate 55 DNA copy number-predicted ecDNAs, we analyzed whole-genome and RNA sequencing data, which identified sequencing reads connecting adjacent focally amplified DNA segments ( Fig. 5c and Supplementary Fig. 6a ), supporting the predictions. After disease recurrence, 23 of 25 tumors preserved at least one cancer driver ecDNA, supporting the notion that ecDNA can prevail following the selective pressure imposed by anticancer therapy. We did not detect any significant correlations between somatic mutations and the presence of ecDNA. We observed a significantly shorter time to second surgery (log-rank test, P = 0.018) for patients whose primary tumor sample was predicted to carry at least one ecDNA, relative to patients with a primary tumor that contained no predicted ecDNA ( Supplementary Fig. 7 ). The presence of an IDH gene mutation in glioma associates with relatively favorable prognosis. The number of IDH-mutant cases was evenly balanced between the ecDNA + (19 of 62) and ecDNA -(13 of 35) groups, suggesting that the significant difference in outcome is independent of ecDNA status. There was no significant difference in time to progression when performing the analysis for the IDH-mutant (log-rank test, P = 0.14) and IDH-wild-type (log-rank test, P = 0.12) tumors separately. This analysis was limited by cohort size and the low sensitivity of the current technology in detecting ecDNA.
Discussion
GBM is a heterogeneous disease that is highly resistant to chemoand radiotherapy. New modalities for treatment are urgently needed. Modeling of tumors through cell culture and orthotopic xenotransplantation is an essential approach for preclinical therapeutic target screening and validation, but in GBM these approaches have yet to result in novel treatments. To what extent these models truthfully recapitulate the parental tumor is a topic of active discussion.
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EcDNAs were discovered decades ago and have been incidentally found to have important roles in tumorigenesis and gliomagenesis in particular 18, 19, [21] [22] [23] 30 . Only recently have we started to understand the magnitude and frequency of these somatic alterations and their impact on tumor evolution 20 . Our results provide direct evi-dence that extrachromosomal amplification of oncogenic elements enhances genomic diversity during tumor evolution. We showed how ecDNA elements can mark major clonal expansions in otherwise-stable genomic backgrounds and related ecDNA presence to tumor progression. Jointly, these findings change views on the R R  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I  I   T 
Fig. 5 | Copy number variant driver genes located on
the potential double-minute regions. a, 66 tumors (33 primary (P), 33 recurrent (R)) from 38 patients were predicted to contain at least one ecDNA that was detected with either a copy number-based method or AmpliconArchitect. Among these, 44 drivergene-harboring ecDNAs were predicted in 25 primary tumors, of which 32 were also detected in the matching recurrent tumors. b, Left, DNA copy number and genomic rearrangements at ecDNA loci that were predicted with the copy number-based approach. Right, representative FISH images in formalin-fixed, paraffin-embedded tissue sections showing amplification of EGFR, MET and MYC (red) and control chromosomal (green) probes. 50 nuclei were examined per sample. Scale bars, 5 μ m. c, DNA copy number-based predictions of ecDNA segments validated using whole-genome or RNA sequencing.
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NATuRe GeNeTIcs evolution of glioma, with potential translation to other ecDNA-carrying cancer types 20 . Little is known about the mechanism through which these elements arise and how they become fixed across a cancer cell population. Our analysis provides a comprehensive study of the fate of chromosomal SNVs and ecDNA oncogene amplifications in GBM in a panel of tumors and derivative models. We further demonstrated the widespread presence of ecDNA-driven oncogene amplification through extensive FISH analysis on sets of paired primary and recurrent tumor samples. Focal gene amplifications have traditionally been recognized as HSRs, and these may originate from chromosomal insertions of ecDNA 25 . We did not observe HSR-like staining patterns for the amplified genes in the metaphase FISH images in this study. HSRs have been observed in GBM 20 and are thought to be less frequent than ecDNA 32 . We captured the early stages of MYC ecDNA expansion in the HF-3016 and HF-2354 tumors with 0.5-2% of cells presenting amplification (< 30 copies/ nucleus), with no evidence of chromosomal-based gene amplification, while in all derived models, as well as the HF-3016 recurrence (HF-3177), the frequency of MYC amplification increased to 100% of cells with up to 100 copies/nucleus. These results are consistent with an origin through excision of a MYC-containing chromosomal DNA segment and end-joining into a circular ecDNA, with subsequent amplification of the ecDNA 30 , followed by selection of MYCamplified cells in vitro and in the recurrent tumor. Spindle assembly and chromosome segregation during mitosis lead to genetically identical daughter cells, containing similar sets of chromosomal sSNVs and DNA copy number alterations. Double minutes/ecDNAs are replicated during S phase, but lack the centromeres that dictate the organization of the mitotic spindle and as a result are randomly distributed across the daughter cells during mitosis. EcDNA elements are thus inherited in a radically different fashion than chromosomes. This divergence in inheritance mechanism may explain, for example, why the evolution of the MET event was not similarly captured by sSNVs ( Fig. 6 ) and shows that extrachromosomal elements have a key role in increasing genomic diversity during tumor evolution. Previous studies have found that extrachromosomal bodies can provide a reservoir for therapeutically targetable genomic alterations 33 . Targeted MET inhibition of MET-amplified GBMs has shown clinical promise 34 , although the variable responses to MET inhibition recorded in our data suggest that the efficacy of single MET-inhibiting agents is influenced by other factors. Our observations extend recent findings that ecDNAs are frequently detected in cancer 20, 22 and demonstrate that detection of point mutations alone is insufficient to accurately delineate the tumor evolutionary process. In analogy to the loss of ecDNAs carrying MET following neurospheroid culturing, loss of EGFR amplification in traditional serum-containing GBM cultures has been observed 35, 36 . The loss of ecDNA EGFR and PDGFRA amplification has also been reported for neurosphere cultures grown in the presence of EGF and bFGF 23, 37 , but not consistently 14 , suggesting that these oncogenes are sometimes but not always indispensable. Withdrawing EGF from the medium was shown to promote maintenance of EGFR amplification 37 . Preservation of EGFR and PDGFRA amplifications in GBM tumors propagated in mouse subcutaneous xenograft tumors has previously been reported 36, 38 . Our results show that ecDNAs carrying amplification of MYC, CDK4, EGFR or PDGFRA were maintained in neurosphere cultures supplemented with EGF and bFGF, at least up to passage 18. The ecDNA amplifications were subsequently maintained in the intracranial xenograft tumors originated by neurosphere implants. Unlike the other ecDNA-amplified oncogenes, we observed that MET ecDNA amplifications dramatically decreased in frequency in the neurosphere cultures and surprisingly reemerged at high frequency after intracranial implantation.
Double minutes and other ecDNAs have been reported in 10-40% of GBMs [21] [22] [23] . These lesions involved frequently amplified oncogenes such as MYC, EGFR, PDGFRA and a region on chromosome 12p that includes CDK4 and MDM2. The ecDNAs reported thus far span up to several megabases in size, and some but not all ecD-NAs can be recognized by an intermittent amplification-deletion DNA copy number pattern 21, 22 . DNA copy number and short-read sequencing technology are limited in their ability to sensitively and specifically detect ecDNAs, in particular with respect to samples that additionally harbor overlapping chromosomal alterations, and we therefore only have incomplete knowledge on the frequency and structure of ecDNA elements 14, [20] [21] [22] [23] . This is reflected by the incomplete overlap in ecDNA predictions from supervised review and the unsupervised AmpliconArchitect method. Long-read technology such as that used in the single-molecule zero-mode waveguides approach from PacBio or nanopore sequencing from Oxford Nanopore Technologies may offer advantages for ecDNA detection. Whether ecDNA size and structure affect the mechanism of tumorigenesis is unclear and is another reflection of the lack of knowledge of extrachromosomal DNA, in particular as an understudied domain in cancer. Our analysis emphasizes the importance of this genomic alteration mechanism for gliomagenesis. Future studies that specifically target the formation of episomal events may lead to therapies to prevent this process from happening. The models we described here may have a pivotal role in evaluating the potential of such approaches.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41588-018-0105-0. 
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Methods
Tumor sample collection and cell culture. Resected brain tumor specimens were collected at Henry Ford Hospital (Detroit, MI) with written informed consent from patients, under a protocol approved by the Henry Ford Hospital Institutional Review Board, and graded pathologically according to the WHO criteria. This work was performed in compliance with all relevant ethical regulations for research using human specimens. A portion of each tumor specimen was snap frozen and stored in liquid nitrogen. An adjacent portion was used for cell culture. Tumors were dissociated enzymatically, and neurospheres enriched in cancer stem-like cells (CSCs) were cultured, as described in detail 39, 40 . Neurosphere cultures were serially passaged in vitro. No mycoplasma contamination was identified in the subset of samples tested. Cells with passages between 7 and 18 were used for mouse implants and molecular analysis, except for those designed 'high passage' , where passage 40 was used.
Patient-derived xenografts. Orthotopic xenografts. Experiments were carried out in compliance with all relevant ethical regulations for animal research under a protocol approved by the Henry Ford Hospital Institutional Animal Care and Use Committee (IACUC). GBM neurosphere cell suspensions were implanted into 8-week-old female nude mice (NCRNU, Taconic Farms) as described 41 . A minimum of eight mice were implanted with each neurosphere line. Animals were anesthetized with a mixture of ketamine and xylazine. Dissociated neurosphere cells (3 × 10 5 ) were injected using a Hamilton syringe at a defined intracranial location: AP + 1.0, ML + 2.5, DV − 3.0. Animals were monitored daily by an observer blinded to the group allocation and sacrificed upon first signs of neurological deficit or weight loss greater than 20%. Brains were dissected and placed in a coronal matrix for 2-mm sections, with the first cut across the implant site. Brain sections were alternately frozen in dry ice and embedded in OCT for storage at − 80 °C or were formalin fixed and paraffin embedded (FFPE).
Subcutaneous xenografts. Dissociated neurosphere cells (1 × 10 6 ) were injected into the flank of nude mice. Animals were sacrificed and tumors were excised when tumor diameter reached 10 mm.
Drug treatment. HF-3077 PDXs were randomized to control and treatment groups. Mice were treated with capmatinib (purchased from Matrix Scientific Products) suspensions in 0.5% methylcellulose/0.1% Tween-80 prepared every week and administered by oral gavage using a 20-gauge × 1.5″ gavage needle (Cadence Science) at a dose of 30 mg/kg once a day (5 d/week) until the end of the study. Control animals received vehicle-only mock gavage. Forty-five days after implant, animals were randomized to control or treatment groups. Each mouse was followed until death with no censoring, and mean survival differences were estimated using a t distribution to estimate 95% confidence intervals. With a sample size of nine mice per group, a two-sided 95% confidence interval for the difference in mean survival would extend 0.92 s.d. from the observed difference in mean survival, assuming the confidence interval is based on the large-sample z statistic. Equivalently, we expected 80% power to detect a difference in mean survival of 1.4 s.d., for the common s.d., when n = 9 animals per group and α = 0.05. Animals were monitored daily and sacrificed upon first signs of neurological deficit or weight loss greater than 20%. Control animals were administered vehicle. Kaplan-Meier survival curves were compared by log-rank test.
To evaluate the brain penetrance of capmatinib, 2 h after administration of the last dose of capmatinib of 30 mg/kg, blood samples were drawn, animals were sacrificed, and brains were dissected and 2-mm coronal sections were frozen in OCT. Tumor tissue was dissected from the frozen blocks. Capmatinib concentration in homogenized tumor tissue and plasma was determined for three treated animals and one control by LC-MS/MS. Xenograft tumor macrodissection of frozen tissue. Brain samples of three randomly selected animals per xenograft line were used. Frozen 2-mm coronal sections were transferred to a cryostat (Cryotome E, ThermoElectronCorporation) set to − 16 °C. Six-micrometer sections were cut and stained with hematoxylin, to locate the tumor. Tumor tissue was excised from the frozen block with a scalpel into a prechilled microtube and stored at − 80 °C.
Nucleic acid isolation. Genomic DNA was isolated from frozen tumor samples, macrodissected xenograft tumors (three biological replicates), and neurosphere cultures using the QIAamp DNA mini kit (Qiagen, 51304), with on-column RNase A digestion, following the manufacturer's instructions. DNA was isolated from blood using the DNA QIAamp Blood kit (Qiagen).
Total RNA was extracted from frozen tumor samples, macrodissected xenograft tumors (three biological replicates), and neurosphere culture using MirVana (Ambion, AM1560), followed by DNase treatment (Ambion, AM1906).
FISH. FISH on matching tumor samples, neurospheres, and PDXs. FISH probes were prepared from purified BAC clones (BACPAC Resource Center; Supplementary  Table 5 ). Probes were labeled with Orange-dUTP or with Green-dUTP (Abbott Molecular), by nick translation.
Metaphase slides were prepared from neurosphere cell cultures that were harvested and fixed in methanol:acetic acid (3:1), according to standard cytogenetic procedures. Tumor touch preparations were prepared by imprinting thawed tumor tissue onto positively charged glass slides and fixing them in methanol:acetic acid (3:1) for 30 min and then air-drying. Frozen tumor and macrodissected xenograft tumor samples were prepared as described 42 . The FISH probes were denatured at 75 °C for 5 min and held at 37 °C for 10-30 min until 10 μ l of probe was applied to each sample slide. Slides were coverslipped and hybridized overnight at 37 °C in the ThermoBrite hybridization system (Abbott Molecular). The posthybridization wash was with 2× SSC/0.2% Tween-20 at 73 °C for 3 min followed by a brief water rinse. Slides were air dried and then counterstained with VECTASHIELD mounting medium with DAPI (Vector Laboratories).
Image acquisition was performed at 1,000× system magnification with a COOL-1300 SpectraCube camera (Applied Spectral Imaging-ASI) mounted on an Olympus BX43 microscope. Images were analyzed using FISHView v7 software (ASI), and 100-200 interphase nuclei were scored for each sample in addition to analysis of 50-100 metaphase spreads for each cell line.
FISH on paired primary and recurrent FFPE gliomas. Fluorescence in situ assays were performed using RPS6/Con 9, CDK4/Con 12, EGFR/Con 7, MYC/Con 8, PDGFRA/Con 4, MET/Con 7, and TERT/Con 5 FISH probes from Empire Genomics. The slides were hybridized with the FISH probes according to the manufacturer's instructions with slight modifications. The slides were then examined under a fluorescence microscope (Nikon 80i) equipped with multiple filters, and signals were manually counted in 50 cells for each slide.
Immunohistochemistry. Sections of formalin-fixed, paraffin-embedded human glioma surgical samples, tumor xenografts, or multicellular spheroids were deparaffinized with xylene and rehydrated through graded alcohol into PBS. Antigens were unmasked by incubation for 10 min in boiling citrate buffer, and sections were stained with anti-MET rabbit monoclonal antibody (D1C2) (Cell Signaling, 8198) or anti-phospho-MET (Tyr1234/1235) rabbit monoclonal antibody (D26) (Cell Signaling, 3077) and visualized with Betazoid DAB (Biocare, BDB2004) and counterstained with Envision Flex Hematoxylin (Dako, K8008). Images were captured using an Eclipse E800M microscope equipped with a Nikon DS-Fi2 color digital camera.
Reverse transcription and PCR. cDNA was prepared from 1 μ g of DNase Itreated total RNA isolated from tumors, neurospheres and xenografts using Superscript III Reverse Transcriptase and oligo(dT) (Thermo Fisher Scientific). cDNA was used as a template for PCR in an iCycler instrument (Bio-Rad), using Platinum Taq DNA Polymerase (Thermo Fisher Scientific). Oligonucleotide sequences are listed in Supplementary Table 6 .
LC-MS/MS quantification of capmatinib in mouse plasma and tumors.
For mouse plasma sample analysis, 25 μ l of each sample was precipitated with 200 μ l of acetonitrile. This suspension was vortexed for 30 min and centrifuged at 4,000 r.p.m. for 15 min, after which 100 μ l of the extract was aliquoted and mixed with 200 μ l of acetonitrile:water (1:2 ratio) prior to LC-MS/MS analysis. The extracted plasma samples were analyzed on a Waters Acquity UPLC system coupled with a Waters Xevo TQ-S triple-quadrupole mass spectrometer operated in positive mode. The capillary voltage was set to 0.5 kV and the collision energy was set to 32 eV. Capmatinib (purchased from Matrix Scientific Products) was separated using a Waters Acquity UPLC BEH C18 column (1.7 µ m, 2.1 × 30 mm) and detected by a multiple-reaction monitoring transition, m/z 413.04 > 354.07. Mobile phase A was 0.1% acetic acid in water and mobile phase B was 0.1% acetic acid in acetonitrile. The liquid chromatography gradient was 10% B (0-0.3 min), 10-95% B (0.3-1.3 min), 95% B (1.3-1.7 min), 10% B (1.7-2.0 min) and the flow rate was 0.5 ml/min. The column temperature was 40 °C. The injection volume was 2 µ l. Under these conditions, the retention time was 0.85 min. The method was validated with an analytical range of 1-1,000 ng of capmatinib in untreated CD-1 mouse plasma. Mouse tumor tissue samples were homogenized in methanol:water (80:20 ratio) to a concentration of 100 mg (tissue)/ml. The homogenates were vortexed for 10 min and centrifuged at 15,000 r.p.m. for 5 min. Then, 100 μ l of the supernatant was transferred into an HPLC vial for LC-MS/MS analysis. The tissue homogenates were analyzed using the same method as described above. The method was validated with an analytical range of 1-1,000 ng/ml of capmatinib in untreated mouse tumor tissue homogenates.
Whole-exome sequencing. Library construction and sequencing. Sequencing libraries were prepared using the KAPA library prep protocol (KK8234, KAPA Biosystems). Exomes were captured using the SureSelect XT Human All Exon V5 kit (Agilent Technologies). Samples were then sequenced 2 × 100 bp to about 340× depth on the Illumina HiSeq 2000 platform.
BAM file generation. The raw output (BCL) files of an Illumina sequencer were converted to FASTQ files using Illumina's offline base-calling software CASAVA, version 1.8.2. The FASTQ files were then aligned to the reference genome (hg19 for human) using BWA version 0.7.0 43 for DNA samples with parameters suitable for a given aligner. The aligned BAM files were subjected to mark duplication, realignment and recalibration using Picard version 1.112 and GATK version 1.5 44 when applicable before any downstream analyses were conducted.
Pacific Biosciences long-read sequencing. Library construction and sequencing. DNA libraries were prepared following the Pacific Biosciences 20-kb Template Preparation Using BluePippin Size-Selection System protocol. No DNA shearing was performed as the samples were already fragmented. The sheared DNA was size selected on a BluePippin system (Sage Science) using a cutoff range of 7 kb to 50 kb. The DNA damage repair, end repair and SMRTbell ligation steps were performed as described in the template preparation protocol with SMRTbell Template Prep kit 1.0 reagents (Pacific Biosciences). The sequencing primer annealing and P6 polymerase binding reactions were performed according to the BindingCalculator (Pacific Biosciences BindingCalculator-master_v2.3.1.1). The libraries were sequenced on a PacBio RSII instrument at a loading concentration (on plate) of 80 pM, 90 pM and 100 pM using the MagBead OneCellPerWell v1 collection protocol, DNA sequencing kit 4.0, SMRT cells v3 and 4-hour movies.
Filtering the sequencing reads. Reads and subreads were filtered on the basis of their length and quality values, using smrtpipe.py from the SMRT-Analysis package. 46 was used for assembling the filtered PacBio sequence subreads with the parameters suggested for low-coverage data. The assembled contigs were aligned by nucmer (version 3.23) 47 to the human genome reference (hg19), and the contigs with sequence fragments that aligned to the MET-CAPZA2 region of chromosome 7 were selected for structural variation analysis. For the selected contigs, we performed a BLASTN search 48 against the mouse genome using the sequence fragments aligned to the MET-CAPZA2 region of hg19 to make sure that they originated from human (Supplementary Table 7 ). Sequence fragments shared by two contigs were identified with pairwise alignment of the contigs using nucmer. Two contigs were considered to be connected only if they shared a sequence fragment that was at least 5,000 bp long with the minimum 99% identity. The high-confidence shared sequence fragments were used to connect the contigs into a circular form in HF-3035. In HF-3077, only two contigs (tig01141776 and tig01141835) were aligned to the MET-CAPZA2 region of chromosome 7, and the two contigs shared a 621-bp sequence with 95.6% identity between the 3′ end of tig01141776 and the 5′ end of tig01141835.
Structural variation analysis. Canu (version 1.2)
Gene fusion and gene expression analysis.
To detect transcript fusions, PRADA aligned RNA-seq reads to a reference database composed of whole-genome sequences (hg19) and transcriptome sequences (Ensembl 64). Two lines of evidence were required for identification of a gene fusion: (i) a minimum of two discordant read pairs mapping to a candidate gene pair and (ii) a minimum of one junction-spanning read mapping to a junction that connected exons between the candidate gene pair, with its pairmate mapping to either of the two genes. Several filters were applied to remove false positives and artifacts, of which the most prominent is based on significant sequence similarity between the two fusion genes (using BLASTN, expect value = 0.01). Gene expression was measured as reads per kilobase per million (RPKM) to normalize for gene length and library size. Specific details of the PRADA pipeline are described elsewhere 45 .
Structural variant detection.
To detect structural variants, we applied SpeedSeq 49 (with default parameters) to whole-genome sequencing from both tumor and matching normal samples. We filtered somatic variants by requiring at least four reads of supporting evidence in a tumor and no reads in its matching normal sample.
EGFR intragenic rearrangement. General User-Defined Supervised Search for
Intragenic Fusion (GUESS-if), a module of PRADA, was also used to search for EGFR intragenic rearrangements, as previously described 11 . In brief, using the same rationale as in PRADA gene fusion identification, GUESS-if looked for spanning reads for abnormal junctions that were not present in known transcripts. To assure high accuracy, we required at least ten reads spanning exons 1-8 of EGFR.
Validation of somatic single-nucleotide variants.
To validate our somatic single-nucleotide mutation calls, we performed targeted resequencing at high coverage (> 1,400× ). We selected 792 unique bases that had been found to be mutated in tumors, neurospheres or xenografts but not in all of them. These sites corresponded to 1,368 sSNVs. In total, 1,287of 1,368 mutations called from the exome sequencing data were detected in the high-coverage data, resulting in a true positive validation rate of 94%. Evidence for recovered somatic mutation was observed in 1,001 of 2,646 wild-type nucleotides. The variant allelic fractions (VAFs), that is, the number of reads harboring the variant allele divided by all reads covering that base, of exome and validation sequencing were highly correlated (Pearson correlation = 0.92).
Somatic single-nucleotide variant calling. Somatic single-nucleotide variants (sSNVs) from tumor and patient-matched normal samples were detected using the MuTect algorithm (version 1.14) with default parameters 50 . The search for somatic small Indels was performed using Pindel 51 with tumor and patient-matched normal samples. All sSNVs and small indels were annotated by ANNOVAR (version 2012-10-23) 52 . Only exonic or splicing sSNVs were selected for analysis. Mutation counts for individual samples are available in Supplementary Table 8 .
Inference of cellular frequency and mutational clusters. We defined the cellular frequency of a mutation as the fraction of cells harboring the mutation. Estimation of cellular frequency was performed using PyClone version 0.12.7 7 . For each set of patient, neurosphere and xenograft samples, PyClone was run on the somatic mutations whose sites were covered over all the samples using multi-sample joint analysis mode with PyClone beta binomial density and parental copy number priors. Allelic copy numbers were estimated by applying Sequenza 53 to exome sequencing data. Default options for PyClone were used. To avoid potential artifacts from sequencing coverage, we limited the analysis to the mutations at the sites covered with at least 50× over all samples from the same patient. PyClone inferred clusters of mutations whose cellular frequencies co-varied over samples. Our analysis was limited to only mutation clusters with at least two mutations.
Removing putative mouse reads in short-read sequencing data. Sequencing reads derived from xenograft samples are a mixture of reads from human and mouse. We utilized Xenome 54 to select sequencing reads arising from human. Then, the human reads selected were aligned to the human genome using the same pipeline as in patient and neurosphere samples.
Identification of copy numbers from low-pass sequence data. We used NBICSeq version 0.5.2 55 with bin size = 1,000 bp and BIC penalty = 3 to estimate somatic copy number alterations in low-pass sequencing data from tumor and patientmatched normal samples.
Detecting TERT promoter mutations. We evaluated whole-genome low-pass sequencing and whole-exome sequencing for the presence of TERT mutations in a supervised way using GATK pileup. We required a minimum of two variant alleles (combined from whole-genome and whole-exome sequencing) for detection of TERT promoter mutations. A c.228 C > T mutation on 5:1295228-1295228 was nature research | life sciences reporting summary June 2017
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed). n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
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Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
Methods -Immunohistochemistry subsection, page 4: "anti-Met rabbit monoclonal antibody (D1C2) (Cell signaling #8198) or anti-phospho-Met (Tyr1234/1235) rabbit monoclonal antibody (D26) (Cell signaling #3077)" The antibodies were validated for recognition of human MET and p-MET by the manufacturer: https:// www.cellsignal.com/products/primary-antibodies/met-d1c2-xp-rabbit-mab/8198; https://www.cellsignal.com/products/primary-antibodies/phospho-met-tyr1234-1235-d26-xp-rabbit-mab/3077. We have further validated these antibodies using breast cancer tissue and MET-amplified glioblastoma tumors as positive controls and glioblastoma tumors not presenting MET amplification as negative controls. 10 . Eukaryotic cell lines a. State the source of each eukaryotic cell line used.
All glioblastoma cells used in this study were derived from patient tumors resected at Henry Ford Hospital.
b. Describe the method of cell line authentication used. The method of authentication was whole genome DNA sequencing of cultured cells and matched patient germline DNA and original tumor.
c. Report whether the cell lines were tested for mycoplasma contamination.
Cells have been tested for mycoplasma contamination using Universal Mycoplasma Detection Kit (ATCC 30-1012K), all tested negative. Supplementary Information, Methods -Tumor sample collection and cell culture subsection, page 1.
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
Only patient-derived cell lines developed in house were used in this study, and none of the cell lines used are listed in the ICLAC database.
Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
Description of research animals
Provide details on animals and/or animal-derived materials used in the study.
Animals used in this study were 8-week old female nude mice (NCRNU, Taconic Farms)
Policy information about studies involving human research participants
Description of human research participants
Describe the covariate-relevant population characteristics of the human research participants.
Biospecimens from 12 deceased patients were used: 6 males and 6 females. Median age at diagnosis was 57 years, ranging from 21 to 82.
